Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
18F-FET PET
biomarkers
glioma
prognosis
targeted therapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
14 02 2019
14 02 2019
Historique:
pubmed:
13
6
2018
medline:
23
4
2020
entrez:
13
6
2018
Statut:
ppublish
Résumé
We aimed to elucidate the place of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas. In 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared. A homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively (P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated (P < 0.0001). TTPmin was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTPmin was longer in isocitrate dehydrogenase (IDH)-mutant tumors (P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade (P < 0.0001) and IDH status (P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTPmin > 25 min (TTPmin ≤ 12.5 min) tumors and IDH-mutant grade II (IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTPmin (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models (P < 0.001). TAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.
Sections du résumé
BACKGROUND
We aimed to elucidate the place of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas.
METHODS
In 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared.
RESULTS
A homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively (P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated (P < 0.0001). TTPmin was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTPmin was longer in isocitrate dehydrogenase (IDH)-mutant tumors (P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade (P < 0.0001) and IDH status (P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTPmin > 25 min (TTPmin ≤ 12.5 min) tumors and IDH-mutant grade II (IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTPmin (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models (P < 0.001).
CONCLUSION
TAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.
Identifiants
pubmed: 29893965
pii: 5035376
doi: 10.1093/neuonc/noy098
pmc: PMC6374762
doi:
Substances chimiques
Biomarkers, Tumor
0
(18F)fluoroethyltyrosine
1326R5J1IA
Tyrosine
42HK56048U
Gadolinium
AU0V1LM3JT
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-284Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Neurooncol. 2008 Jun;88(2):205-10
pubmed: 18317691
Curr Neurol Neurosci Rep. 2010 May;10(3):224-31
pubmed: 20425038
Int J Cancer. 2015 May 1;136(9):2132-45
pubmed: 25311315
Neuroimage Clin. 2016 Dec 18;13:386-394
pubmed: 28116231
J Clin Oncol. 1990 Jul;8(7):1277-80
pubmed: 2358840
Cancer. 2006 Mar 15;106(6):1372-81
pubmed: 16470609
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Nat Rev Neurol. 2017 Jun;13(6):340-351
pubmed: 28497806
BMC Clin Pathol. 2012 Feb 28;12:4
pubmed: 22373026
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1105-14
pubmed: 26666239
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286
Neuro Oncol. 2018 Jan 22;20(2):279-288
pubmed: 29016996
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Nucl Med. 2013 Dec;54(12):2046-54
pubmed: 24159047
Adv Tech Stand Neurosurg. 2010;35:65-79
pubmed: 20102111
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
J Nucl Med. 2007 Jul;48(7):1047-52
pubmed: 17574979
Neuro Oncol. 2011 Mar;13(3):307-16
pubmed: 21292686
Br J Radiol. 2006 Aug;79(944):652-8
pubmed: 16641420
J Clin Oncol. 2009 Dec 10;27(35):5874-80
pubmed: 19901110
Neurology. 2002 Sep 24;59(6):947-9
pubmed: 12297589
Memo. 2012 Sep;5(3):223-227
pubmed: 23864911
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Neuro Oncol. 2012 Dec;14(12):1473-80
pubmed: 23090986
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
Radiology. 2016 Feb;278(2):546-53
pubmed: 26348233
Acta Neuropathol. 2010 Dec;120(6):707-18
pubmed: 21088844
EJNMMI Res. 2017 Aug 16;7(1):64
pubmed: 28815478
Neuro Oncol. 2009 Apr;11(2):176-82
pubmed: 18697954
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):443-451
pubmed: 29043400
Intractable Rare Dis Res. 2015 Nov;4(4):165-9
pubmed: 26668776
Acta Neurochir (Wien). 2014 Aug;156(8):1427-40
pubmed: 24792966
Oncologist. 2014 Apr;19(4):403-13
pubmed: 24664484
Neuro Oncol. 2015 Sep;17(9):1293-300
pubmed: 26008606
J Nucl Med. 2014 Feb;55(2):198-203
pubmed: 24379223
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931